These results support the speculation that combined modality cancer therapies designed to increase metabolic oxidative stress and cancer cell killing by inhibiting the pentose cycle as well as Trx-mediated hydroperoxide metabolism may provide a useful adjuvant for the treatment of prostate and breast cancer. Here, TXN is linked to cancer.